盐酸坦洛新(坦索罗辛)缓释片治疗良性前列腺增生症的临床疗效观察  

Clinical observation of tamsulosin hydrochloride sustained-release tablets in the treatment of benign prostatic hyperplasia

作　　者：黄中力[1] 朱育春[1] 解志远[1] 

机构地区：[1]四川大学华西医院泌尿外科,四川成都610041

出　　处：《现代泌尿外科杂志》2010年第1期43-44,共2页Journal of Modern Urology

摘　　要：目的探讨盐酸坦洛新（坦索罗辛）缓释片对良性前列腺增生症的治疗效果。方法自2006年9月～2007年8月，选择良性前列腺增生症患者83例，给予高选择性a，受体阻断剂盐酸坦洛新（坦索罗辛）缓释片0．2mg，每晚1次，连服4周。记录治疗前后患者的国际前列腺症状评分（IPSS）、最大尿流率（MFR）、平均尿流率（AFR）、残余尿量（Ru）、前列腺体积、血压等变化，并进行比较。结果经过4周服药治疗，患者的IPSS评分及残余尿量明显下降（P〈0．01），而MFR与AFR均明显增加，差异有统计学意义（P〈0．01）。前列腺体积及血压治疗前后比较差异无统计学意义（P〉0．05）。结论盐酸坦洛新（坦索罗辛）对良性前列腺增生症的症状改善、提高患者的生活质量等方面具有良好的临床实用价值，且副作用较小，值得临床广泛应用。Objective To evaluate the validity of tamsulosin hydrochloride sustained-release tablets for the treatment of benign prostatic hyperplasia. Methods Since Sep. 2006 to Aug. 2007, 83 patients with benign prostatic hyperplasia were selected, and highly selective ul receptor antagonist tamsulosin hydrochlorideustained-release tablets were administered 0.2 mg Qn for four weeks. The International Prostate Symptom Score（IPSS）, maximum flow rate （MFR）, the average flow rate （AFR）, residual urine volume （RU）, size of the prostate, and changes in blood pressure before and after treatment were recorded and compared. Results After 4 weeks of medication treatment, the patients＇ IPSS and RU decreased significantly （P〈0. 01）, while MFR and AFR increased significantly （P〈0.01）. Prostate volume before and after treatment had no significant difference （P〉0.05）. Normal blood pressure and high blood pressure groups were compared. There was no significant difference in the systolic blood pressure and diastolic blood pressure （P 〉 0. 05）. Conclusiofi Tamsulosin hydrochloride can improve the quality of life and relieve the symptom of patients with benign prostatic hyperplasia. With good clinical value and fewer side-effects,it is worth wide clinical application.

关 键 词：良性前列腺增生症 药物治疗 盐酸坦洛新(坦索罗辛)缓释片 

分 类 号：R697.32[医药卫生—泌尿科学]